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Value of additional chemotherapy for malaria in pregnancy
In The Lancet Global Health, Silke Fernandes and 
colleagues1 provide an important and timely assessment 
of the cost-eﬀ ectiveness of increasing the doses of 
intermittent preventive treatment for malaria during 
pregnancy (IPTp) from two doses to three or more doses, 
as currently recommended by the WHO.
This analysis provides compelling evidence that the 
incremental reduction in low birthweight noted in 
women who receive additional doses of sulfadoxine 
pyrimethamine (SP) during pregnancy2 will be highly 
cost-eﬀ ective when included as part of standard 
antenatal care in most areas of sustained malaria 
transmission in Africa.
The demonstration that monthly IPTp-SP is 
cost-eﬀ ective is important to both researchers and 
policymakers, and this result has clear implications for 
improving the health of both expectant mothers and 
their infants in this region. An estimated 32 million 
pregnancies occurred in such areas in 2010,3 which would 
have the potential to lead to an estimated 0·7 million 
low birthweight deliveries attributable to malaria if these 
women were not protected from infection.4
However, some key questions remain concerning 
how best to provide protection from malaria during 
pregnancy. Perhaps the most pressing is why, despite 
IPTp-SP having demonstrable cost-eﬀ ectiveness with 
the previously recommended two doses5 and antenatal 
care coverage now being high across much of Africa, 
the proportion of women receiving even two courses of 
IPTp in many areas remains low.6 
As the authors suggest, one contributing factor to this 
low uptake might be the emergence of resistance to SP, 
particularly in eastern Africa. SP is no longer eﬃ  cacious 
for case management in such settings, and perception 
of SP as an ineﬀ ective drug might be undermining 
IPTp-SP. This factor has prompted researchers to look 
at alternatives to IPTp-SP such as the use of more 
eﬃ  cacious or longer-lasting artemisinin combination 
therapies (ACTs), either on the basis of positive diagnosis 
from a rapid diagnostic test (RDT) at an antenatal care 
visit, or as an alternative presumptive therapy.7 
It is reassuring that SP remains eﬀ ective against low 
birthweight, the main determinant of cost-eﬀ ectiveness 
in this analysis, in all but the most highly resistant areas 
(those with super-resistance conferred by six sequential 
resistance mutations).2 Although in these areas the 
eﬃ  cacy of SP is now substantially inhibited,8,9 this 
constitutes a small proportion of east Africa. However, 
parasites with the preceding quintuple mutation are 
widespread throughout the region,10 highlighting the 
need to continually monitor the progress of resistance 
and its eﬀ ect on IPTp-SP.
Estimates used in this analysis suggest that additional 
doses of SP have the same proportional eﬀ ect on all-
cause low birthweight in both moderate and low-
resistance settings.7 This measure, however, depends 
on the proportion of all-cause low birthweight that 
is attributable to malaria. As a result, diﬀ erences in 
SP eﬀ ectiveness could feasibly be disguised if there 
is a higher proportion of malaria-attributable low 
birthweight in areas where SP is less eﬀ ective. Similar 
arguments can be made about the potential limitations 
of using the impact of SP on all-cause low birthweight 
to compare eﬀ ectiveness between higher and lower 
transmission settings.
The very fact that providing a greater number of doses 
of IPTp-SP is incrementally eﬀ ective, even in settings 
where the parasite is sensitive,2 also highlights the 
potential beneﬁ t of interventions using more eﬀ ective 
drugs. This ﬁ nding means there is either scope to 
improve clearance of existing infections or, if the gain 
from more IPTp-SP courses is due to longer prophylaxis, 
a longer-acting drug might achieve similar beneﬁ ts with 
fewer administrations.
Data were also insuﬃ  cient for Fernandes and 
colleagues1 to extend their analysis to areas of low or 
unstable transmission, a situation that will hopefully 
become more common as malaria control progresses 
across Africa. In such situations, symptomatic disease 
during pregnancy is likely to cause an increased 
proportion of the overall burden,11 and understanding 
how malaria-attributable risk of low birthweight and 
immunity to both placental infection and symptomatic 
disease change as transmission falls will become an 
increasingly important issue. 
Any alternative strategy to IPTp-SP is likely to have 
its own challenges: concerns remain about providing 
ACTs during pregnancy to uninfected women; testing 
using RDTs is likely to be more costly, might miss 
some infections, and means that uninfected women 
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do not beneﬁ t from prophylaxis; and switching to case 
management of symptomatic women leaves many 
asymptomatic women unprotected from prolonged 
placental infection. The analysis by Fernandes and 
colleagues1 is a clear benchmark by which to judge these 
various merits and limitations and thus is an important 
step towards ensuring a much higher proportion of 
women receive adequate care for malaria in pregnancy.
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